215 related articles for article (PubMed ID: 25520086)
1. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
[TBL] [Abstract][Full Text] [Related]
2. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
Khallouf H; Märten A; Serba S; Teichgräber V; Büchler MW; Jäger D; Schmidt J
J Immunother; 2012 Apr; 35(3):245-53. PubMed ID: 22421942
[TBL] [Abstract][Full Text] [Related]
3. 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands.
Zhao L; Wang WJ; Zhang JN; Zhang XY
Asian Pac J Cancer Prev; 2014; 15(9):4039-44. PubMed ID: 24935593
[TBL] [Abstract][Full Text] [Related]
4. Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA.
Wan LL; Zhang DQ; Zhang JN; Ren LQ
J Zhejiang Univ Sci B; 2017 Jun; 18(6):522-531. PubMed ID: 28585428
[TBL] [Abstract][Full Text] [Related]
5. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
[TBL] [Abstract][Full Text] [Related]
6. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
7. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
8. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
10. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells.
Yang H; Dithmar S; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2056-64. PubMed ID: 15223777
[TBL] [Abstract][Full Text] [Related]
11. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
12. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
13. Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE.
Narumi K; Miyakawa R; Ueda R; Hashimoto H; Yamamoto Y; Yoshida T; Aoki K
J Immunol; 2015 Jun; 194(11):5539-48. PubMed ID: 25911757
[TBL] [Abstract][Full Text] [Related]
14. Platelets impair natural killer cell reactivity and function in endometriosis through multiple mechanisms.
Du Y; Liu X; Guo SW
Hum Reprod; 2017 Apr; 32(4):794-810. PubMed ID: 28184445
[TBL] [Abstract][Full Text] [Related]
15. [Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response].
Li XF; Chen Q; Ye YB; Fan LF; Chen MS; Li JY; Chen HQ; Chen SP; Zhou ZF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):160-4. PubMed ID: 17490545
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
[TBL] [Abstract][Full Text] [Related]
17. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
Bui JD; Carayannopoulos LN; Lanier LL; Yokoyama WM; Schreiber RD
J Immunol; 2006 Jan; 176(2):905-13. PubMed ID: 16393975
[TBL] [Abstract][Full Text] [Related]
18. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8
Hu J; Bernatchez C; Zhang L; Xia X; Kleinerman ES; Hung MC; Hwu P; Li S
Cancer Immunol Res; 2017 Apr; 5(4):300-311. PubMed ID: 28223282
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
20. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.
Hu J; Zhu S; Xia X; Zhang L; Kleinerman ES; Li S
Mol Cancer; 2014 Feb; 13():34. PubMed ID: 24565056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
